The relation between Helicobacter pylori and ulcerative colitis

Objective & Hypothesis:Besides some genetic explanations of the native course of ulcerative colitis (UC), the most attributable factors are pathogenic bacterial agents.

📊

Key Findings & Data:There are some conflicting data about the relationship between Helicobacter pylori and the rate of UC in the literature.

💡

Conclusion & Impact:It could not be determined whether the low positivity of H. pylori in extended UC cases was due to immunosuppressive drugs or to the UC itself.

🔬Design:Research Article

📍Scope:Comprehensive Sample

⚙️Variables:Ulcerative colitis · Helicobacter pylori · immunosuppressive drugs

Abstract

Besides some genetic explanations of the native course of ulcerative colitis (UC), the most attributable factors are pathogenic bacterial agents. There are some conflicting data about the relationship between Helicobacter pylori and the rate of UC in the literature. Therefore, we aimed to investigate the rate of H. pylori in UC patients. Materials and methods: Forty-nine individuals diagnosed with UC who had undergone upper gastrointestinal tract endoscopy for different reasons were included in the study. The presence of H. pylori in the stomach was checked by histopathological examination. Results: H. pylori positivity was present in 57.1% of patients with UC. Interestingly, H. pylori positivity was lower (11.1%) in pancolitis patients compared to those presenting with more limited illnesses. There were no relationships among the severity of the underlying disease, medication already used, and H. pylori positivity rate. Conclusion: The extension of UC is important for the positivity rate of H. pylori. It could not be determined whether the low positivity of H. pylori in extended UC cases was due to immunosuppressive drugs or to the UC itself.

Özet

Besides some genetic explanations of the native course of ulcerative colitis (UC), the most attributable factors are pathogenic bacterial agents. There are some conflicting data about the relationship between Helicobacter pylori and the rate of UC in the literature. Therefore, we aimed to investigate the rate of H. pylori in UC patients. Materials and methods: Forty-nine individuals diagnosed with UC who had undergone upper gastrointestinal tract endoscopy for different reasons were included in the study. The presence of H. pylori in the stomach was checked by histopathological examination. Results: H. pylori positivity was present in 57.1% of patients with UC. Interestingly, H. pylori positivity was lower (11.1%) in pancolitis patients compared to those presenting with more limited illnesses. There were no relationships among the severity of the underlying disease, medication already used, and H. pylori positivity rate. Conclusion: The extension of UC is important for the positivity rate of H. pylori. It could not be determined whether the low positivity of H. pylori in extended UC cases was due to immunosuppressive drugs or to the UC itself.

Keywords

Ulcerative colitis Helicobacter pylori immunosuppressive drugs

🔖

Cite This Article

CANER, S., ALTINBAŞ, A., YEŞİL, Y., BEYAZIT, Y., YILMAZ, B., YÜKSEL, O. (2014). The relation between Helicobacter pylori and ulcerative colitis. Turkish Journal of Medical Sciences, Cilt: 44 - Sayı: 5, 820–823. https://ajindex.com/articles/186262

📄 Full Text PDF Viewer

Open in New Tab ↗

↗New Tab

📄

PDF görüntüleyici hazırlanıyor...

References (13)

Neuman MG, Nanau RM. Inflammatory bowel disease: role of diet, microbiota, life style. Transl Res 2012;160: 29–44
Altınbas A, Koybasıoglu F, Aktas E, Yılmaz B, Coban S. Ulcerative colitis triggered by pegylated interferon alone therapy for chronic hepatitis C. Inflamm Bowel Dis 2011;17: 1050
Louis E, Van Kemseke C, Latour P, Belaiche J, Reenaers C. Genetics and environment in chronic inflammatory bowel diseases. Rev Med Liege 2012; 67: 298–304 (article in French with English abstract)
Dogruman-Al F, Simsek Z, Boorom K, Ekici E, Sahin M, Tuncer C, Kustimur S, Altinbas A. Comparison of methods for detection of Blastocystis infection in routinely submitted stool samples, and also in IBS/IBD Patients in Ankara, Turkey. PLoS One 2010; 5: e15484
Kandulski A, Selgrad M, Malfertheiner P. Helicobacter pylori infection: a clinical overview. Dig Liver Dis 2008; 40: 619–626
Smolka AJ, Backert S. How Helicobacter pylori infection controls gastric acid secretion. J Gastroenterol 2012; 47: 609–618
Figura N, Franceschi F, Santucci A, Bernardini G, Gasbarrini G, Gasbarrini A. Extragastric manifestations of Helicobacter pylori infection. Helicobacter 2010; 15 (Suppl. 1): 60–68
Hasni SA. Role of Helicobacter pylori infection in autoimmune diseases. Curr Opin Rheumatol 2012; 24: 429–434. 9. el-Omar E, Penman I, Cruikshank G, Dover S, Banerjee S, Williams C, McColl KE. Low prevalence of Helicobacter pylori in inflammatory bowel disease: association with sulphasalazine. Gut 1994; 35: 1385–1388
Pearce CB, Duncan HD, Timmis L, Green JR. Assessment of the prevalence of infection with Helicobacter pylori in patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol 2000; 12: 439–443
Piodi LP, Bardella M, Rocchia C, Cesana BM, Baldassarri A, Quatrini M. Possible protective effect of 5-aminosalicylic acid on Helicobacter pylori infection in patients with inflammatory bowel disease. J Clin Gastroenterol 2003; 36: 22–25
Triantafillidis JK, Gikas A, Apostolidiss N, Merikas E, Mallass E, Peros G. The low prevalence of Helicobacter infection in patients with inflammatory bowel disease could be attributed to previous antibiotic treatment. Am J Gastroenterol 2003; 98: 1213–1214
Dixon MF, Genta RM, Yardley JH, Correa P. Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol 1996; 20: 1161–1181
Truelove SC, Witts LJ. Cortison